The Global Influenza Market
REPORT SCOPE:
This BCC Research report is designed to be a helpful business tool that provides a thorough evaluation of the market for influenza vaccines, therapeutics and diagnostics. The geographic scope of this study is global, with emphasis on U.S. and European data. The report identifies markets in general segments: Vaccines, Therapeutics and Diagnostics. Each market segment discussion provides detailed information based on product categories, uses of products, forecasts and competitive analyses. Additionally, the study covers some of the most significant issues, trends and market factors.
REPORT INCLUDES:
This BCC Research report is designed to be a helpful business tool that provides a thorough evaluation of the market for influenza vaccines, therapeutics and diagnostics. The geographic scope of this study is global, with emphasis on U.S. and European data. The report identifies markets in general segments: Vaccines, Therapeutics and Diagnostics. Each market segment discussion provides detailed information based on product categories, uses of products, forecasts and competitive analyses. Additionally, the study covers some of the most significant issues, trends and market factors.
REPORT INCLUDES:
- 25 data tables and 77 additional tables
- An overview of the global influenza market
- Analyses of global market trends, with data from 2016 and 2017, and projections of compound annual growth rates (CAGRs) through 2022
- Identification of segments with high growth potential and their future applications
- Explanation of major drivers and regional dynamics of the market and current trends within the industry
- Detailed profiles of major vendors in the market, including Alere Inc., MedImmune, LLC, Cepheid Inc., GlaxoSmithKline plc and Qiagen N.V.
CHAPTER 1 INTRODUCTION
Influenza Overview
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
The Influenza Market: Summary of Major Markets
CHAPTER 3 INDUSTRY OVERVIEW AND BACKGROUND
Overview
History of the Market
Epidemics and Pandemics in History
Virus Mutations
Influenza Types
WHO and CDC Influenza Response
World Health Organization
Centers for Disease Control and Prevention
U.S. Viral Surveillance
FDA's Vaccine and Related Biological Products Advisory Committee and Vaccine Composition
Vaccine Recommendations
Vaccine Effectiveness
Universal Vaccine
Population Demographics and Influenza Incidence/Mortality
Global Demographics
Global Life Expectancy
Influenza Incidence and Mortality
The 2017-2018 Influenza Season (Through January 2018)
CHAPTER 4 GLOBAL INFLUENZA VACCINE MARKET
Overview
Current Vaccines
The Global Influenza Vaccine Market
Seasonal versus Pandemic Sales
Regional Market Summary
The U.S. Influenza Vaccine Market
History of Vaccine Manufacturer Participation in the United States
The European Influenza Vaccine Market
Global Competitor Analysis
Influenza Vaccine Developments
Clinical Trials
CHAPTER 5 GLOBAL INFLUENZA THERAPEUTICS MARKET
Overview
Current Therapies
Generic Availability
The Global Influenza Therapeutics Market
Seasonal versus Pandemic Sales
Regional Market Summary
The U.S. Influenza Therapeutics Market
The European Influenza Therapeutics Market
Global Competitor Analysis
Influenza Treatment Developments
Clinical Trials
CHAPTER 6 GLOBAL INFLUENZA DIAGNOSTIC MARKET
Overview
Test Descriptions1
Product Descriptions
Laboratory Services
The Global Influenza Diagnostic Market
Regional Market Summary
Global Competitor Analysis
CHAPTER 7 INFLUENZA PANDEMIC IMPACT
Epidemic/Pandemic Threat
H1N1 Outbreak 2009 (Swine Flu)
Rapid Diagnostics
Pandemic Testing
Seasonal Influenza Tests
Avian Flu
Avian Flu Surveillance
The WHO and Containment for Pandemic Influenza
International Influenza Vaccine Stockpile Orders
Pre-Pandemic Vaccination
Biomedical Advanced Research and Development Authority (BARDA)
Antiviral Resistance
Recreated Viruses
Immaterialized Market Risk
Media Coverage and Vaccinations
Pandemic Preparedness Plans
Infrared Sensors and Thermal Imagers
The United States
Japan
China
Brazil
United Kingdom
CHAPTER 8 PATENT REVIEW/ NEW DEVELOPMENTS
Overview
Influenza Patent Review by Year
Influenza Patent Review by Country
Influenza Patent Review by Assignee
Massachusetts Institute of Technology (MIT)
Seqirus U.K. Limited
Academia Sinica
Celltrion Inc.
Icahn School of Medicine at Mount Sinai
Shionogi & Co. Ltd.
Vertex Pharmaceuticals Inc.
Xiamen University
CHAPTER 9 ANALYSIS OF MARKET OPPORTUNITIES
Overview of Influenza Market Trends
Total Market Analysis
Regional Market Summary
CHAPTER 10 COMPANY PROFILES
Significant Company Acquisitions
ALERE INC.
MedImmune/AstraZeneca
MEDIMMUNE INC.
BECTON DICKINSON AND COMPANY
CEPHEID
DAIICHI SANKYO
GLAXOSMITHKLINE PLC
HOLOGIC INC
LUMINEX CORP.
MITSUBISHI TANABE PHARMA CORP.
MYLAN N.V.
ORASURE TECHNOLOGIES
QIAGEN N.V.
QUIDEL CORP.
ROCHE
SANOFI/SANOFI PASTEUR
SEKISUI DIAGNOSTICS LLC
SEQIRUS
CHAPTER 11 APPENDIX
Manufacturers and Developers
Approved WHO Influenza Centers
List of Acronyms
Glossary of Terms
Influenza Overview
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
The Influenza Market: Summary of Major Markets
CHAPTER 3 INDUSTRY OVERVIEW AND BACKGROUND
Overview
History of the Market
Epidemics and Pandemics in History
Virus Mutations
Influenza Types
WHO and CDC Influenza Response
World Health Organization
Centers for Disease Control and Prevention
U.S. Viral Surveillance
FDA's Vaccine and Related Biological Products Advisory Committee and Vaccine Composition
Vaccine Recommendations
Vaccine Effectiveness
Universal Vaccine
Population Demographics and Influenza Incidence/Mortality
Global Demographics
Global Life Expectancy
Influenza Incidence and Mortality
The 2017-2018 Influenza Season (Through January 2018)
CHAPTER 4 GLOBAL INFLUENZA VACCINE MARKET
Overview
Current Vaccines
The Global Influenza Vaccine Market
Seasonal versus Pandemic Sales
Regional Market Summary
The U.S. Influenza Vaccine Market
History of Vaccine Manufacturer Participation in the United States
The European Influenza Vaccine Market
Global Competitor Analysis
Influenza Vaccine Developments
Clinical Trials
CHAPTER 5 GLOBAL INFLUENZA THERAPEUTICS MARKET
Overview
Current Therapies
Generic Availability
The Global Influenza Therapeutics Market
Seasonal versus Pandemic Sales
Regional Market Summary
The U.S. Influenza Therapeutics Market
The European Influenza Therapeutics Market
Global Competitor Analysis
Influenza Treatment Developments
Clinical Trials
CHAPTER 6 GLOBAL INFLUENZA DIAGNOSTIC MARKET
Overview
Test Descriptions1
Product Descriptions
Laboratory Services
The Global Influenza Diagnostic Market
Regional Market Summary
Global Competitor Analysis
CHAPTER 7 INFLUENZA PANDEMIC IMPACT
Epidemic/Pandemic Threat
H1N1 Outbreak 2009 (Swine Flu)
Rapid Diagnostics
Pandemic Testing
Seasonal Influenza Tests
Avian Flu
Avian Flu Surveillance
The WHO and Containment for Pandemic Influenza
International Influenza Vaccine Stockpile Orders
Pre-Pandemic Vaccination
Biomedical Advanced Research and Development Authority (BARDA)
Antiviral Resistance
Recreated Viruses
Immaterialized Market Risk
Media Coverage and Vaccinations
Pandemic Preparedness Plans
Infrared Sensors and Thermal Imagers
The United States
Japan
China
Brazil
United Kingdom
CHAPTER 8 PATENT REVIEW/ NEW DEVELOPMENTS
Overview
Influenza Patent Review by Year
Influenza Patent Review by Country
Influenza Patent Review by Assignee
Massachusetts Institute of Technology (MIT)
Seqirus U.K. Limited
Academia Sinica
Celltrion Inc.
Icahn School of Medicine at Mount Sinai
Shionogi & Co. Ltd.
Vertex Pharmaceuticals Inc.
Xiamen University
CHAPTER 9 ANALYSIS OF MARKET OPPORTUNITIES
Overview of Influenza Market Trends
Total Market Analysis
Regional Market Summary
CHAPTER 10 COMPANY PROFILES
Significant Company Acquisitions
ALERE INC.
MedImmune/AstraZeneca
MEDIMMUNE INC.
BECTON DICKINSON AND COMPANY
CEPHEID
DAIICHI SANKYO
GLAXOSMITHKLINE PLC
HOLOGIC INC
LUMINEX CORP.
MITSUBISHI TANABE PHARMA CORP.
MYLAN N.V.
ORASURE TECHNOLOGIES
QIAGEN N.V.
QUIDEL CORP.
ROCHE
SANOFI/SANOFI PASTEUR
SEKISUI DIAGNOSTICS LLC
SEQIRUS
CHAPTER 11 APPENDIX
Manufacturers and Developers
Approved WHO Influenza Centers
List of Acronyms
Glossary of Terms
LIST OF TABLES
Table A: Report Sources
Summary Table: Global Influenza Market, by Product Type, Through 2022
Table 1: Distribution of Fatal Cases of H1N1 Pandemic, by WHO Region, 2009-2010
Table 2: CDC Estimates of 2009 H1N1 Cases and Related Hospitalizations and Deaths, by Age Group, April 2009-March 13, 2010
Table 3: Cumulative Number of Confirmed Cases of H7N9, by Region, 2013 to October 2016
Table 4: Viral Surveillance Share, by Flu Seasons and Influenza Virus Type, 2005-2018
Table 5: Influenza Virus Recommendations for U.S. Influenza Seasons, 2003-2018
Table 6: Thimerosal Content of Influenza Vaccines
Table 7: CDC Influenza Vaccine Recommendations
Table 8: Adjusted Vaccine Effectiveness Estimates for Influenza Seasons, 2005-2017
Table 9: Global Population, by Selected Age Group, 2010-2050
Table 10: Global Population Average Growth Rate, by Broad Age Group, 2010-2050
Table 11: Global Population, by Selected Country, Through 2020
Table 12: Global Life Expectancy at Birth, by Selected Country, 1980-2020
Table 13: U.S. Impact of 2009 H1N1 Influenza, Cases and Related Hospitalizations and Deaths, by Age Group, April 2009-2010
Table 14: U.S. Influenza Reporting Data Cumulative, Since October 1, 2017 (Week 40) to January 13, 2018 (Week 2)
Table 15: Examples of Marketed Seasonal Influenza Vaccine Products
Table 16: FDA Seasonal Influenza Vaccine Approvals, Based on Adult Dosage, 2017-2018
Table 17: Examples of Approved Pandemic Influenza Vaccine Products
Table 18: Global Market for Influenza Vaccines, by Manufacturer, Through 2022
Table 19: Global Market for Influenza Vaccines, by Country, 2017
Table 20: Global Market for Influenza Vaccines, by Region, Through 2022
Table 21: U.S. Market for Influenza Vaccines, by Manufacturer, Through 2022
Table 22: Influenza Vaccine Manufacturer Participation in the U.S., 2004-2018
Table 23: European Market for Influenza Vaccines, by Manufacturer, Through 2022
Table 24: European Market for Influenza Vaccines, by Country, 2017
Table 25: Global Competitor Market Analysis for Influenza Vaccines, 2017
Table 26: Clinical Trials for Influenza Prevention (Vaccines and Biologics), by Selected Country and Trial Status
Table 27: Altimmune Influenza Vaccine Pipeline
Table 28: BIKEN Influenza Vaccine Pipeline
Table 29: BiondVax Pharmaceuticals Influenza Vaccine Pipeline
Table 30: hangchun BCHT Biotechnology Influenza Vaccine Pipeline
Table 31: Eurocine Vaccines Influenza Vaccine Pipeline
Table 32: FluGen Influenza Vaccine Pipeline
Table 33: Folia Biotech Vaccines Influenza Vaccine Pipeline
Table 34: Green Cross Corp. Influenza Vaccine Pipeline
Table 35: Institute of Vaccines and Medical Biologicals, Vietnam Influenza Vaccine Pipeline
Table 36: Medicago Influenza Vaccine Pipeline
Table 37: MedImmune Influenza Vaccine Pipeline
Table 38: Mitsubishi Tanabe Influenza Vaccine Pipeline
Table 39: Moderna Therapeutics Influenza Vaccine Pipeline
Table 40: NanoBio Corp. Influenza Vaccine Pipeline
Table 41: Nitto Denko Influenza Vaccine Pipeline
Table 42: Novavax Influenza Vaccine Pipeline
Table 43: Pantec Biosolutions Influenza Vaccine Pipeline
Table 44: Sanofi Pasteur Influenza Vaccine Pipeline
Table 45: Seqirus Influenza Vaccine Pipeline
Table 46: Vaccitech Influenza Vaccine Pipeline
Table 47: Vaxart Influenza Vaccine Pipeline
Table 48: Marketed Influenza Therapies, by Manufacturer, 2017
Table 49: Generic FDA Approvals for Influenza Therapies
Table 50: Global Market for Influenza Therapeutics, by Manufacturer, Through 2022
Table 51: Global Market for Influenza Therapeutics, by Region, Through 2022
Table 52: U.S. Market for Influenza Therapeutics, by Manufacturer, Through 2022
Table 53: European Market for Influenza Therapeutics, by Manufacturer, Through 2022
Table 54: Global Competitor Market Analysis for Influenza Therapeutics, 2017
Table 55: Clinical Trials for Influenza Therapeutics by Selected Country and Trial Status
Table 56: Amarillo Biosciences Influenza Treatment Pipeline
Table 57: Ansun BioPharma Influenza Treatment Pipeline
Table 58: AstraZeneca Influenza Treatment Pipeline
Table 59: Daiichi Sankyo Influenza Treatment Pipeline
Table 60: Emergent BioSolutions Influenza Treatment Pipeline
Table 61: GlaxoSmithKline Influenza Treatment Pipeline
Table 62: Hemispherx Biopharma Influenza Treatment Pipeline
Table 63: Il-Yang Influenza Treatment Pipeline
Table 64: Janssen Pharmaceutical Co. Influenza Treatment Pipeline
Table 65: NanoViricides Influenza Vaccine Pipeline
Table 66: Sarepta Therapeutics Influenza Treatment Pipeline
Table 67: Shionogi Influenza Treatment Pipeline
Table 68: Toyama Chemical Influenza Treatment Pipeline
Table 69: Visterra Influenza Treatment Pipeline
Table 70: Influenza Diagnostic Table
Table 71: Clinical Considerations of Rapid Testing During High Influenza Prevalence
Table 72: Clinical Considerations of Rapid Testing During Low Influenza Prevalence
Table 73: Selected Marketed Influenza Products, January 2018
Table 74: Selected Rapid Influenza Tests Average Price
Table 75: Global Providers of Test Services
Table 76: Global Market for Influenza Diagnostics, by Product Classification, Through 2022
Table 77: Global Market for Influenza Diagnostics, by Region, Through 2022
Table 78: CLIA-waived Approvals for Influenza Indications in the U.S., 2000-2017
Table 79: Global Competitor Market Analysis for Influenza Diagnostics, 2017
Table 80: Estimated Incidence of Pandemic Influenza, Severe Outbreaks Based on 2017- Population, U.S. Census Bureau International Database, Selected Countries
Table 81: Countries Affected by Current CDC and USDA Bird Import Restrictions
Table 82: Countries with Temporary Restrictions on Importation of Avian Commodities, CDC and USDA Restrictions
Table 83: WHO-Reported Cases of Avian Influenza A/(H5N1) in Humans, 2003-2017
Table 84: Neuraminidase Inhibitor Resistance Testing Results on Samples Collected Since October 1, 2017
Table 85: Essential and Desirable Elements of the WHO Influenza Pandemic Preparedness Plan
Table 86: Japan’s Action Plan for Influenza Pandemic Preparedness
Table 87: China Influenza Pandemic Warning Levels
Table 88: Brazil Influenza Pandemic Warning Levels and Action
Table 89: Patents for Influenza, by Year Issued, 2002-2017
Table 90: Recent Patents for Influenza Technology, by Patent Number
Table 91: Recent Patents for Influenza Technology, by Country
Table 92: Number of U.S. Patents, by Influenza Market Competitor
Table 93: Influenza Vaccine Market, by Drivers and Challenges
Table 94: Influenza Therapeutic Market, by Drivers and Challenges
Table 95: Influenza Diagnostic Market, by Drivers and Challenges
Table 96: Global Influenza Market, by Product Segment, Through 2022
Table 97: Global Influenza Market, by Region, Through 2022
Table 98: U.S. Influenza Market, by Segment, Through 2022
Table 99: European Influenza Market, by Segment, Through 2022
Table 100: Approved WHO Influenza Centers, by Region
Table 101: Abbreviations Used in Influenza Markets
Table 102: Glossary of Terms Used in Influenza Markets
Table A: Report Sources
Summary Table: Global Influenza Market, by Product Type, Through 2022
Table 1: Distribution of Fatal Cases of H1N1 Pandemic, by WHO Region, 2009-2010
Table 2: CDC Estimates of 2009 H1N1 Cases and Related Hospitalizations and Deaths, by Age Group, April 2009-March 13, 2010
Table 3: Cumulative Number of Confirmed Cases of H7N9, by Region, 2013 to October 2016
Table 4: Viral Surveillance Share, by Flu Seasons and Influenza Virus Type, 2005-2018
Table 5: Influenza Virus Recommendations for U.S. Influenza Seasons, 2003-2018
Table 6: Thimerosal Content of Influenza Vaccines
Table 7: CDC Influenza Vaccine Recommendations
Table 8: Adjusted Vaccine Effectiveness Estimates for Influenza Seasons, 2005-2017
Table 9: Global Population, by Selected Age Group, 2010-2050
Table 10: Global Population Average Growth Rate, by Broad Age Group, 2010-2050
Table 11: Global Population, by Selected Country, Through 2020
Table 12: Global Life Expectancy at Birth, by Selected Country, 1980-2020
Table 13: U.S. Impact of 2009 H1N1 Influenza, Cases and Related Hospitalizations and Deaths, by Age Group, April 2009-2010
Table 14: U.S. Influenza Reporting Data Cumulative, Since October 1, 2017 (Week 40) to January 13, 2018 (Week 2)
Table 15: Examples of Marketed Seasonal Influenza Vaccine Products
Table 16: FDA Seasonal Influenza Vaccine Approvals, Based on Adult Dosage, 2017-2018
Table 17: Examples of Approved Pandemic Influenza Vaccine Products
Table 18: Global Market for Influenza Vaccines, by Manufacturer, Through 2022
Table 19: Global Market for Influenza Vaccines, by Country, 2017
Table 20: Global Market for Influenza Vaccines, by Region, Through 2022
Table 21: U.S. Market for Influenza Vaccines, by Manufacturer, Through 2022
Table 22: Influenza Vaccine Manufacturer Participation in the U.S., 2004-2018
Table 23: European Market for Influenza Vaccines, by Manufacturer, Through 2022
Table 24: European Market for Influenza Vaccines, by Country, 2017
Table 25: Global Competitor Market Analysis for Influenza Vaccines, 2017
Table 26: Clinical Trials for Influenza Prevention (Vaccines and Biologics), by Selected Country and Trial Status
Table 27: Altimmune Influenza Vaccine Pipeline
Table 28: BIKEN Influenza Vaccine Pipeline
Table 29: BiondVax Pharmaceuticals Influenza Vaccine Pipeline
Table 30: hangchun BCHT Biotechnology Influenza Vaccine Pipeline
Table 31: Eurocine Vaccines Influenza Vaccine Pipeline
Table 32: FluGen Influenza Vaccine Pipeline
Table 33: Folia Biotech Vaccines Influenza Vaccine Pipeline
Table 34: Green Cross Corp. Influenza Vaccine Pipeline
Table 35: Institute of Vaccines and Medical Biologicals, Vietnam Influenza Vaccine Pipeline
Table 36: Medicago Influenza Vaccine Pipeline
Table 37: MedImmune Influenza Vaccine Pipeline
Table 38: Mitsubishi Tanabe Influenza Vaccine Pipeline
Table 39: Moderna Therapeutics Influenza Vaccine Pipeline
Table 40: NanoBio Corp. Influenza Vaccine Pipeline
Table 41: Nitto Denko Influenza Vaccine Pipeline
Table 42: Novavax Influenza Vaccine Pipeline
Table 43: Pantec Biosolutions Influenza Vaccine Pipeline
Table 44: Sanofi Pasteur Influenza Vaccine Pipeline
Table 45: Seqirus Influenza Vaccine Pipeline
Table 46: Vaccitech Influenza Vaccine Pipeline
Table 47: Vaxart Influenza Vaccine Pipeline
Table 48: Marketed Influenza Therapies, by Manufacturer, 2017
Table 49: Generic FDA Approvals for Influenza Therapies
Table 50: Global Market for Influenza Therapeutics, by Manufacturer, Through 2022
Table 51: Global Market for Influenza Therapeutics, by Region, Through 2022
Table 52: U.S. Market for Influenza Therapeutics, by Manufacturer, Through 2022
Table 53: European Market for Influenza Therapeutics, by Manufacturer, Through 2022
Table 54: Global Competitor Market Analysis for Influenza Therapeutics, 2017
Table 55: Clinical Trials for Influenza Therapeutics by Selected Country and Trial Status
Table 56: Amarillo Biosciences Influenza Treatment Pipeline
Table 57: Ansun BioPharma Influenza Treatment Pipeline
Table 58: AstraZeneca Influenza Treatment Pipeline
Table 59: Daiichi Sankyo Influenza Treatment Pipeline
Table 60: Emergent BioSolutions Influenza Treatment Pipeline
Table 61: GlaxoSmithKline Influenza Treatment Pipeline
Table 62: Hemispherx Biopharma Influenza Treatment Pipeline
Table 63: Il-Yang Influenza Treatment Pipeline
Table 64: Janssen Pharmaceutical Co. Influenza Treatment Pipeline
Table 65: NanoViricides Influenza Vaccine Pipeline
Table 66: Sarepta Therapeutics Influenza Treatment Pipeline
Table 67: Shionogi Influenza Treatment Pipeline
Table 68: Toyama Chemical Influenza Treatment Pipeline
Table 69: Visterra Influenza Treatment Pipeline
Table 70: Influenza Diagnostic Table
Table 71: Clinical Considerations of Rapid Testing During High Influenza Prevalence
Table 72: Clinical Considerations of Rapid Testing During Low Influenza Prevalence
Table 73: Selected Marketed Influenza Products, January 2018
Table 74: Selected Rapid Influenza Tests Average Price
Table 75: Global Providers of Test Services
Table 76: Global Market for Influenza Diagnostics, by Product Classification, Through 2022
Table 77: Global Market for Influenza Diagnostics, by Region, Through 2022
Table 78: CLIA-waived Approvals for Influenza Indications in the U.S., 2000-2017
Table 79: Global Competitor Market Analysis for Influenza Diagnostics, 2017
Table 80: Estimated Incidence of Pandemic Influenza, Severe Outbreaks Based on 2017- Population, U.S. Census Bureau International Database, Selected Countries
Table 81: Countries Affected by Current CDC and USDA Bird Import Restrictions
Table 82: Countries with Temporary Restrictions on Importation of Avian Commodities, CDC and USDA Restrictions
Table 83: WHO-Reported Cases of Avian Influenza A/(H5N1) in Humans, 2003-2017
Table 84: Neuraminidase Inhibitor Resistance Testing Results on Samples Collected Since October 1, 2017
Table 85: Essential and Desirable Elements of the WHO Influenza Pandemic Preparedness Plan
Table 86: Japan’s Action Plan for Influenza Pandemic Preparedness
Table 87: China Influenza Pandemic Warning Levels
Table 88: Brazil Influenza Pandemic Warning Levels and Action
Table 89: Patents for Influenza, by Year Issued, 2002-2017
Table 90: Recent Patents for Influenza Technology, by Patent Number
Table 91: Recent Patents for Influenza Technology, by Country
Table 92: Number of U.S. Patents, by Influenza Market Competitor
Table 93: Influenza Vaccine Market, by Drivers and Challenges
Table 94: Influenza Therapeutic Market, by Drivers and Challenges
Table 95: Influenza Diagnostic Market, by Drivers and Challenges
Table 96: Global Influenza Market, by Product Segment, Through 2022
Table 97: Global Influenza Market, by Region, Through 2022
Table 98: U.S. Influenza Market, by Segment, Through 2022
Table 99: European Influenza Market, by Segment, Through 2022
Table 100: Approved WHO Influenza Centers, by Region
Table 101: Abbreviations Used in Influenza Markets
Table 102: Glossary of Terms Used in Influenza Markets
LIST OF FIGURES
Summary Figure: Global Influenza Market, by Product Type, 2016-2022
Figure 1: Viral Surveillance Share, by flu seasons and Influenza Virus Type, 2005-2018
Figure 2: Recommendations Regarding Influenza Vaccination of Persons Allergic to Eggs: Advisory Committee on Immunization Practices for U.S. Influenza Season, 2017-2018
Figure 3: Global Population, by Selected Age Group, 2010-2050
Figure 4: Global Population Average Growth Rate, by Broad Age Group, 2010-2050
Figure 5: Global Population, by Selected Country, 2010-2020
Figure 6: Global Life Expectancy at Birth, by Selected Country, 1980-2020
Figure 7: Weekly Influenza Surveillance Report, 2017-2018
Figure 8: Global Market for Influenza Vaccines, by Manufacturer, 2016-2022
Figure 9: Global Market for Influenza Vaccines, by Country, 2017
Figure 10: Global Market Share of Influenza Vaccine Sales, by Country, 2017
Figure 11: Global Market for Influenza Vaccines, by Vaccine Type, 2007-2017
Figure 12: Global Market for Influenza Vaccines, by Region, 2016-2022
Figure 13: Global Market Share of Influenza Vaccine Sales, by Region, 2017
Figure 14: U.S. Market for Influenza Vaccines, by Manufacturer, 2016-2022
Figure 15: U.S. Market Share of Influenza Vaccine Sales, by Manufacturer, 2017
Figure 16: Influenza Vaccine Manufacturer Lot Share in the U.S., 2017-2018
Figure 17: European Market for Influenza Vaccines, by Manufacturer, 2016-2022
Figure 18: European Market Share of Influenza Vaccine Sales, by Manufacturer, 2017
Figure 19: European Market for Influenza Vaccines, by Country, 2017
Figure 20: European Market Share of Influenza Vaccine Sales, by Country, 2017
Figure 21: Global Competitor Market Analysis for Influenza Vaccines, 2017
Figure 22: Global Market Share of Influenza Vaccine Sales, by Manufacturer, 2017
Figure 23: Global Market for Influenza Therapeutics, by Manufacturer, 2016-2022
Figure 24: Global Market for Influenza Therapeutics, by Contract Type, 2007-2017
Figure 25: Global Market for Influenza Therapeutics, by Region, 2016-2022
Figure 26: Global Market Share of Influenza Therapeutics Sales, by Region, 2017
Figure 27: U.S. Market for Influenza Therapeutics, by Manufacturer, 2016-2022
Figure 28: U.S. Market Share of Influenza Therapeutics Sales, by Manufacturer, 2017
Figure 29: European Market for Influenza Therapeutics, by Manufacturer, 2016-2022
Figure 30: European Market Share of Influenza Therapeutic Sales, by Manufacturer, 2017
Figure 31: Global Competitor Market Analysis for Influenza Therapeutics, 2017
Figure 32: Global Market Share of Influenza Therapeutic Sales, by Manufacturer, 2017
Figure 33: Global Market for Influenza Diagnostics, by Product Classification, 2016-2022
Figure 34: Global Market Share of Influenza Diagnostics, by Product Classification, 2017
Figure 35: Share of Conventional Laboratory Influenza Diagnostic Sales, by Product Type, 2017
Figure 36: Share of Rapid Influenza Diagnostic Sales, by Product Type, 2017
Figure 37: Global Market for Influenza Diagnostics, by Region, 2016-2022
Figure 38: Global Market Share of Influenza Diagnostics Sales, by Region, 2017
Figure 39: CLIA-waived Approvals for Influenza Indications in the U.S., 2000-2017
Figure 40: Global Competitor Market Analysis for Influenza Diagnostics, 2017
Figure 41: Global Market Share of Influenza Diagnostic Sales, by Manufacturer, 2017
Figure 42: WHO-Reported Cases of Avian Influenza A/(H5N1) in Humans, 2003-2017
Figure 43: Number of Approved WHO Influenza Centers, by WHO Broad Region
Figure 44: Targeted Pre-Pandemic Influenza Vaccine Stockpiles, Based on Population Demands for Selected Countries
Figure 45: Patents for Influenza, by Year Issued, 2002-2017
Figure 46: Recent Patents for Influenza Technology, by Country
Figure 47: Global Influenza Market, by Product Segment, 2016-2022
Figure 48: Global Influenza Market Share, by Product Segment, 2017
Figure 49: Global Influenza Market, by Region, 2016-2022
Figure 50: Global Influenza Market Share, by Region, 2017
Figure 51: U.S. Influenza Market, by Segment, 2016-2022
Figure 52: U.S. Influenza Market Share, by Segment, 2017
Figure 53: European Influenza Market, by Segment, 2016-2022
Figure 54: European Influenza Market Share, by Segment, 2017
COMPANIES MENTIONED
Alere Inc.
BECTON DICKINSON AND COMPANY
CEPHEID
CSL LIMITED
DAIICHI SANKYO
DANAHER CORP.
GLAXOSMITHKLINE PLC
HOLOGIC INC
LUMINEX CORP.
MEDIMMUNE INC.
MedImmune/AstraZeneca
MITSUBISHI TANABE PHARMA CORP.
MYLAN N.V.
ORASURE TECHNOLOGIES
QIAGEN N.V.
QUIDEL CORP.
ROCHE
SANOFI
SANOFI/SANOFI PASTEUR
SEKISUI DIAGNOSTICS LLC
SEQIRUS
Summary Figure: Global Influenza Market, by Product Type, 2016-2022
Figure 1: Viral Surveillance Share, by flu seasons and Influenza Virus Type, 2005-2018
Figure 2: Recommendations Regarding Influenza Vaccination of Persons Allergic to Eggs: Advisory Committee on Immunization Practices for U.S. Influenza Season, 2017-2018
Figure 3: Global Population, by Selected Age Group, 2010-2050
Figure 4: Global Population Average Growth Rate, by Broad Age Group, 2010-2050
Figure 5: Global Population, by Selected Country, 2010-2020
Figure 6: Global Life Expectancy at Birth, by Selected Country, 1980-2020
Figure 7: Weekly Influenza Surveillance Report, 2017-2018
Figure 8: Global Market for Influenza Vaccines, by Manufacturer, 2016-2022
Figure 9: Global Market for Influenza Vaccines, by Country, 2017
Figure 10: Global Market Share of Influenza Vaccine Sales, by Country, 2017
Figure 11: Global Market for Influenza Vaccines, by Vaccine Type, 2007-2017
Figure 12: Global Market for Influenza Vaccines, by Region, 2016-2022
Figure 13: Global Market Share of Influenza Vaccine Sales, by Region, 2017
Figure 14: U.S. Market for Influenza Vaccines, by Manufacturer, 2016-2022
Figure 15: U.S. Market Share of Influenza Vaccine Sales, by Manufacturer, 2017
Figure 16: Influenza Vaccine Manufacturer Lot Share in the U.S., 2017-2018
Figure 17: European Market for Influenza Vaccines, by Manufacturer, 2016-2022
Figure 18: European Market Share of Influenza Vaccine Sales, by Manufacturer, 2017
Figure 19: European Market for Influenza Vaccines, by Country, 2017
Figure 20: European Market Share of Influenza Vaccine Sales, by Country, 2017
Figure 21: Global Competitor Market Analysis for Influenza Vaccines, 2017
Figure 22: Global Market Share of Influenza Vaccine Sales, by Manufacturer, 2017
Figure 23: Global Market for Influenza Therapeutics, by Manufacturer, 2016-2022
Figure 24: Global Market for Influenza Therapeutics, by Contract Type, 2007-2017
Figure 25: Global Market for Influenza Therapeutics, by Region, 2016-2022
Figure 26: Global Market Share of Influenza Therapeutics Sales, by Region, 2017
Figure 27: U.S. Market for Influenza Therapeutics, by Manufacturer, 2016-2022
Figure 28: U.S. Market Share of Influenza Therapeutics Sales, by Manufacturer, 2017
Figure 29: European Market for Influenza Therapeutics, by Manufacturer, 2016-2022
Figure 30: European Market Share of Influenza Therapeutic Sales, by Manufacturer, 2017
Figure 31: Global Competitor Market Analysis for Influenza Therapeutics, 2017
Figure 32: Global Market Share of Influenza Therapeutic Sales, by Manufacturer, 2017
Figure 33: Global Market for Influenza Diagnostics, by Product Classification, 2016-2022
Figure 34: Global Market Share of Influenza Diagnostics, by Product Classification, 2017
Figure 35: Share of Conventional Laboratory Influenza Diagnostic Sales, by Product Type, 2017
Figure 36: Share of Rapid Influenza Diagnostic Sales, by Product Type, 2017
Figure 37: Global Market for Influenza Diagnostics, by Region, 2016-2022
Figure 38: Global Market Share of Influenza Diagnostics Sales, by Region, 2017
Figure 39: CLIA-waived Approvals for Influenza Indications in the U.S., 2000-2017
Figure 40: Global Competitor Market Analysis for Influenza Diagnostics, 2017
Figure 41: Global Market Share of Influenza Diagnostic Sales, by Manufacturer, 2017
Figure 42: WHO-Reported Cases of Avian Influenza A/(H5N1) in Humans, 2003-2017
Figure 43: Number of Approved WHO Influenza Centers, by WHO Broad Region
Figure 44: Targeted Pre-Pandemic Influenza Vaccine Stockpiles, Based on Population Demands for Selected Countries
Figure 45: Patents for Influenza, by Year Issued, 2002-2017
Figure 46: Recent Patents for Influenza Technology, by Country
Figure 47: Global Influenza Market, by Product Segment, 2016-2022
Figure 48: Global Influenza Market Share, by Product Segment, 2017
Figure 49: Global Influenza Market, by Region, 2016-2022
Figure 50: Global Influenza Market Share, by Region, 2017
Figure 51: U.S. Influenza Market, by Segment, 2016-2022
Figure 52: U.S. Influenza Market Share, by Segment, 2017
Figure 53: European Influenza Market, by Segment, 2016-2022
Figure 54: European Influenza Market Share, by Segment, 2017
COMPANIES MENTIONED
Alere Inc.
BECTON DICKINSON AND COMPANY
CEPHEID
CSL LIMITED
DAIICHI SANKYO
DANAHER CORP.
GLAXOSMITHKLINE PLC
HOLOGIC INC
LUMINEX CORP.
MEDIMMUNE INC.
MedImmune/AstraZeneca
MITSUBISHI TANABE PHARMA CORP.
MYLAN N.V.
ORASURE TECHNOLOGIES
QIAGEN N.V.
QUIDEL CORP.
ROCHE
SANOFI
SANOFI/SANOFI PASTEUR
SEKISUI DIAGNOSTICS LLC
SEQIRUS
